Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients

Meghan E. Sise, Donald F. Chute, Jenna L. Gustafson, David Wojciechowski, Nahel Elias, Raymond T. Chung, Winfred W. Williams

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Long wait times for kidney transplant and the high risk of mortality on dialysis have prompted investigation into strategies to increase organ allocation and decrease discard rates of potentially viable kidneys. Organs from hepatitis C virus (HCV) antibody positive donors are often rejected; nearly 500 HCV-infected kidneys are discarded annually in the United States. Due the opioid epidemic, the number of HCV-infected donors has increased because of a rise in both new HCV infections and drug-related deaths. In the past 5 years, HCV has been transformed into a curable illness with direct-acting antiviral therapies (DAAs) that are effective in >95% of patients treated and are extremely well tolerated. Recent data has shown several direct-acting antiviral combinations are safe and effective after kidney transplant, and can achieve the same high cure rate seen in the general population and without increasing the rate of acute rejection. Because of this, strategies to decrease discard of HCV-infected organs have been devised. Two recent studies have transplanted HCV-uninfected dialysis patients with kidneys from donors actively infected with HCV; recipients were treated with DAA in the peri-transplant period. More research is needed to determine the safety and efficacy of this approach, but it has the potential to dramatically increase the donor pool of available kidneys, shorten waitlist times and ultimately decreases mortality in patients waiting for kidney transplant.

Original languageEnglish (US)
Pages (from-to)S71-S80
JournalHemodialysis International
Volume22
DOIs
StatePublished - Apr 2018
Externally publishedYes

Fingerprint

Hepacivirus
Transplantation
Kidney
Tissue Donors
Antiviral Agents
Transplants
Dialysis
Hepatitis C Antibodies
Mortality
Virus Diseases
Opioid Analgesics
Safety
Therapeutics
Research
Pharmaceutical Preparations
Population

Keywords

  • Direct Acting Antivirals
  • Hepatitis C
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Nephrology

Cite this

Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients. / Sise, Meghan E.; Chute, Donald F.; Gustafson, Jenna L.; Wojciechowski, David; Elias, Nahel; Chung, Raymond T.; Williams, Winfred W.

In: Hemodialysis International, Vol. 22, 04.2018, p. S71-S80.

Research output: Contribution to journalReview article

Sise, Meghan E. ; Chute, Donald F. ; Gustafson, Jenna L. ; Wojciechowski, David ; Elias, Nahel ; Chung, Raymond T. ; Williams, Winfred W. / Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients. In: Hemodialysis International. 2018 ; Vol. 22. pp. S71-S80.
@article{c0e783b5f85043dbbf55aba53e84bb66,
title = "Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients",
abstract = "Long wait times for kidney transplant and the high risk of mortality on dialysis have prompted investigation into strategies to increase organ allocation and decrease discard rates of potentially viable kidneys. Organs from hepatitis C virus (HCV) antibody positive donors are often rejected; nearly 500 HCV-infected kidneys are discarded annually in the United States. Due the opioid epidemic, the number of HCV-infected donors has increased because of a rise in both new HCV infections and drug-related deaths. In the past 5 years, HCV has been transformed into a curable illness with direct-acting antiviral therapies (DAAs) that are effective in >95{\%} of patients treated and are extremely well tolerated. Recent data has shown several direct-acting antiviral combinations are safe and effective after kidney transplant, and can achieve the same high cure rate seen in the general population and without increasing the rate of acute rejection. Because of this, strategies to decrease discard of HCV-infected organs have been devised. Two recent studies have transplanted HCV-uninfected dialysis patients with kidneys from donors actively infected with HCV; recipients were treated with DAA in the peri-transplant period. More research is needed to determine the safety and efficacy of this approach, but it has the potential to dramatically increase the donor pool of available kidneys, shorten waitlist times and ultimately decreases mortality in patients waiting for kidney transplant.",
keywords = "Direct Acting Antivirals, Hepatitis C, Transplantation",
author = "Sise, {Meghan E.} and Chute, {Donald F.} and Gustafson, {Jenna L.} and David Wojciechowski and Nahel Elias and Chung, {Raymond T.} and Williams, {Winfred W.}",
year = "2018",
month = "4",
doi = "10.1111/hdi.12650",
language = "English (US)",
volume = "22",
pages = "S71--S80",
journal = "Hemodialysis International",
issn = "1492-7535",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients

AU - Sise, Meghan E.

AU - Chute, Donald F.

AU - Gustafson, Jenna L.

AU - Wojciechowski, David

AU - Elias, Nahel

AU - Chung, Raymond T.

AU - Williams, Winfred W.

PY - 2018/4

Y1 - 2018/4

N2 - Long wait times for kidney transplant and the high risk of mortality on dialysis have prompted investigation into strategies to increase organ allocation and decrease discard rates of potentially viable kidneys. Organs from hepatitis C virus (HCV) antibody positive donors are often rejected; nearly 500 HCV-infected kidneys are discarded annually in the United States. Due the opioid epidemic, the number of HCV-infected donors has increased because of a rise in both new HCV infections and drug-related deaths. In the past 5 years, HCV has been transformed into a curable illness with direct-acting antiviral therapies (DAAs) that are effective in >95% of patients treated and are extremely well tolerated. Recent data has shown several direct-acting antiviral combinations are safe and effective after kidney transplant, and can achieve the same high cure rate seen in the general population and without increasing the rate of acute rejection. Because of this, strategies to decrease discard of HCV-infected organs have been devised. Two recent studies have transplanted HCV-uninfected dialysis patients with kidneys from donors actively infected with HCV; recipients were treated with DAA in the peri-transplant period. More research is needed to determine the safety and efficacy of this approach, but it has the potential to dramatically increase the donor pool of available kidneys, shorten waitlist times and ultimately decreases mortality in patients waiting for kidney transplant.

AB - Long wait times for kidney transplant and the high risk of mortality on dialysis have prompted investigation into strategies to increase organ allocation and decrease discard rates of potentially viable kidneys. Organs from hepatitis C virus (HCV) antibody positive donors are often rejected; nearly 500 HCV-infected kidneys are discarded annually in the United States. Due the opioid epidemic, the number of HCV-infected donors has increased because of a rise in both new HCV infections and drug-related deaths. In the past 5 years, HCV has been transformed into a curable illness with direct-acting antiviral therapies (DAAs) that are effective in >95% of patients treated and are extremely well tolerated. Recent data has shown several direct-acting antiviral combinations are safe and effective after kidney transplant, and can achieve the same high cure rate seen in the general population and without increasing the rate of acute rejection. Because of this, strategies to decrease discard of HCV-infected organs have been devised. Two recent studies have transplanted HCV-uninfected dialysis patients with kidneys from donors actively infected with HCV; recipients were treated with DAA in the peri-transplant period. More research is needed to determine the safety and efficacy of this approach, but it has the potential to dramatically increase the donor pool of available kidneys, shorten waitlist times and ultimately decreases mortality in patients waiting for kidney transplant.

KW - Direct Acting Antivirals

KW - Hepatitis C

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85045896032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045896032&partnerID=8YFLogxK

U2 - 10.1111/hdi.12650

DO - 10.1111/hdi.12650

M3 - Review article

C2 - 29694722

AN - SCOPUS:85045896032

VL - 22

SP - S71-S80

JO - Hemodialysis International

JF - Hemodialysis International

SN - 1492-7535

ER -